Study of adherence to therapy in patients with schizophrenia depending on the duration of the disease and its clinical manifestations. Results of the original study

Study of adherence to therapy in patients with schizophrenia depending on the duration of the disease and its clinical manifestations. Results of the original study

 

Authors

 

A.S. Ozornin

Federal State Budgetary Educational Institution of Higher Education “Chita State Medical Academy” of the Ministry of Health of the Russian Federation, Chita, Russian Federation

A.A. Platonova

Federal State Budgetary Educational Institution of Higher Education “Chita State Medical Academy” of the Ministry of Health of the Russian Federation, Chita, Russian Federation

A.T. Garmaeva

Federal State Budgetary Educational Institution of Higher Education “Chita State Medical Academy” of the Ministry of Health of the Russian Federation, Chita, Russian Federation

A.S. Novikova

Federal State Budgetary Educational Institution of Higher Education “Chita State Medical Academy” of the Ministry of Health of the Russian Federation, Chita, Russian Federation

A.V. Sakharov

Federal State Budgetary Educational Institution of Higher Education “Chita State Medical Academy” of the Ministry of Health of the Russian Federation, Chita, Russian Federation

 

https://doi.org/10.26617/1810-3111-2024-3(124)-36-44

 

Journal: Siberian Herald of Psychiatry and Addiction Psychiatry. 2024; 3 (124):  36-44.

 

Abstract

Introduction. A significant number of patients with schizophrenia do not take the recommended medications due to subjective intolerance to therapy, negative attitude towards medications, lack of critical attitude towards the condition, while non-compliance with the treatment regimen leads to worsening of the mental disorder. The currently available data on the relationship between compliance and clinical symptoms of schizophrenia, the features of its course are scattered and contradictory, therefore further research on treatment adherence depending on the clinical manifestations of the disease is necessary. Objective: to study adherence to therapy in patients with schizophrenia depending on the duration of the mental disorder and its main clinical symptoms. Material and Methods. The study included 48 patients diagnosed with “Paranoid schizophrenia” (F20.0), mean age was 33±8 years. All patients received antipsychotic therapy for 6 weeks before inclusion in the study. The clinical-psychopathological, psychometric and statistical methods were used. The psychodiagnostic questionnaires for assessing the symptoms of schizophrenia, the severity of anxiety and the cognitive impairment were as follows: The Positive and Negative Syndrome Scale (PANSS), the Hamilton Rating Scale (HARS), the Montreal Cognitive Assessment (MoCA). The study of adherence to therapy was conducted using the Russian generic questionnaire for quantitative assessment of adherence to treatment (KOP-25). Results. It was found that only 27.1% of patients with schizophrenia had strong adherence to treatment, in this group of patients, individuals with a disease duration of up to 5 years and leading hallucinatory-paranoid symptoms in the clinical picture of psychosis prevailed, while the presence of paranoid or affective-paranoid syndrome reduced adherence to therapy. In patients with schizophrenia with the disorder duration of more than 5 years, a positive correlation was documented between adherence to treatment and the total score on the Montreal Cognitive Scale. Conclusion. Thus, in schizophrenic patients with the disease duration of up to 5 years, adherence to therapy depends on the clinical manifestations of the previous psychosis, and in patients with the mental disorder duration of more than 5 years ‒ on the severity of cognitive impairment.

 

Keywords: schizophrenia, antipsychotics, adherence to treatment, compliance, generic questionnaire for quantitative assessment of adherence.

 

Article (pdf)

 

Contacts

This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Materials  

For citation: Ozornin A.S., Platonova A.A., Garmaeva A.T., Novikova A.S., Sakharov A.V. Study of adherence to therapy in patients with schizophrenia depending on the duration of the disease and its clinical manifestations. Results of the original study. Siberian Herald of Psychiatry and Addiction Psychiatry.2024; 3 (124): 36-44. https://doi.org/10.26617/1810-3111-2024-3(124)-36-44

 

REFERENCES

  1. Fakorede OO, Ogunwale A, Akinhanmi AO. Disability among patients with schizophrenia: A hospital-based study. Int J Soc Psychiatry. 2020 Mar;66(2):179-187. doi: 10.1177/0020764019894608. Epub 2019 Dec 30. PMID: 31885321.
  2. Ishigooka J, Nakagome K, Ohmori T, Iwata N, Inada K, Iga JI, Kishi T, Fujita K, Kikuchi Y, Shichijo T, Tabuse H, Koretsune S, Terada H, Terada H, Kishimoto T, Tsutsumi Y, Kanda Y, Ohi K, Sekiyama K. Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second-generation antipsychotics: 52-week evaluation of JUMPs, a randomized, open-label study. Psychiatry Clin Neurosci. 2022 Jan;76(1):22-31. doi: 10.1111/pcn.13304. Epub 2021 Nov 17. PMID: 34626144; PMCID: PMC9299006.
  3. Mohammed F, Geda B, Yadeta TA, Dessie Y. Antipsychotic medication non-adherence and factors associated among patients with schizophrenia in eastern Ethiopia. BMC Psychiatry. 2024 Feb 7;24(1):108. doi: 10.1186/s12888-024-05554-0. PMID: 38326836; PMCID: PMC10851518.
  4. García S, Martínez-Cengotitabengoa M, López-Zurbano S, Zorrilla I, López P, Vieta E, González-Pinto A. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: A systematic review. J Clin Psychopharmacol. 2016 Aug;36(4):355-71. doi: 10.1097/JCP.0000000000000523. PMID: 27307187; PMCID: PMC4932152.
  5. Li IH, Hsieh WL, Liu WI. A systematic review and meta-analysis of the effectiveness of adherence therapy and its treatment duration in patients with schizophrenia spectrum disorders. Patient Prefer Adherence. 2023 Mar 21;17:769-780. doi: 10.2147/PPA.S401650. PMID: 36974078; PMCID: PM*C10039634.
  6. Semahegn A, Torpey K, Manu A, Assefa N, Tesfaye G, Ankomah A. Psychotropic medication non-adherence and associated factors among adult patients with major psychiatric disorders: a protocol for a systematic review. Syst Rev. 2018 Jan 22;7(1):10. doi: 10.1186/s13643-018-0676-y. PMID: 29357926; PMCID: PMC5778728.
  7. Yu W, Tong J, Sun X, Chen F, Zhang J, Pei Y, Zhang T, Zhang J, Zhu B. Analysis of medication adherence and its influencing factors in patients with schizophrenia in the Chinese institutional environment. Int J Environ Res Public Health. 2021 Apr 29;18(9):4746. doi: 10.3390/ijerph18094746. PMID: 33946836; PMCID: PMC8125059.
  8. Eticha T, Teklu A, Ali D, Solomon G, Alemayehu A. Factors associated with medication adherence among patients with schizophrenia in Mekelle, Northern Ethiopia. PLoS One. 2015 Mar 27;10(3):e0120560. doi: 10.1371/journal.pone.0120560. PMID: 25816353; PMCID: PMC4376899.
  9. Karabulut B, Uslu E. Schizophrenia and medication adherence: Associated factors. Arch Psychiatr Nurs. 2024 Apr;49:47-54. doi: 10.1016/j.apnu.2024.01.015. Epub 2024 Jan 25. PMID: 38734454.
  10. Daderwal MC, Sreeraj VS, Suhas S, Rao NP, Venkatasubramanian G. Montreal Cognitive Assessment (MoCA) and Digit Symbol Substitution Test (DSST) as a screening tool for evaluation of cognitive deficits in schizophrenia. Psychiatry Res. 2022 Oct;316:114731. doi: 10.1016/j.psychres.2022.114731. Epub 2022 Jul 17. PMID: 35926360.
  11. NikolaevNA, SkirdenkoYuP. Russian generic questionnaire for evaluation of compliance to drug therapy. Clinical Pharmacology and Therapy.2018;27(1):74-78 (in Russian).
  12. Shettima F, Sheikh T, Wakil M, Wakama I, Abdulaziz M, Rabbebe I. Prevalence and predictors of medication adherence among patients with schizophrenia in Maiduguri, Northeastern Nigeria. West Afr J Med. 2023 Nov 10;40(11 Suppl 1):S21-S22. PMID: 37976234.
  13. Ali MM, Taha MM, Ahmed AE, Ali S, Baiti MA, Alhazmi AA, Alfaifi BA, Majrabi RQ, Khormi NQ, Hakami AA, Alqaari RA, Alhasani RA, Abdelwahab SI. Psychotropic medication adherence and its associated factors among schizophrenia patients: Exploring the consistency of adherence scales. Cureus. 2023 Sep 28;15(9):e46118. doi: 10.7759/cureus.46118. PMID: 37900367; PMCID: PMC10612138.
  14. Kule M, Kaggwa MM. Adherence to typical antipsychotics among patients with schizophrenia in Uganda: A cross-sectional study. Schizophr Res Treatment. 2023 Feb 3;2023:7035893. doi: 10.1155/2023/7035893. PMID: 36778520; PMCID: PMC9918368.
  15. Wang H, Zhang Y, Liu J, Chi R, Wu T, Zhang T, Zhang L, Jiang K, Qiu H, Dong W, Si T. Persistence with and adherence to paliperidone palmitate once-monthly injection for schizophrenia treatment in China and Japan. J Clin Psychiatry. 2021 Dec 28;83(1):20m13850. doi: 10.4088/JCP.20m13850. PMID: 34963203.
  16. Højlund M, Correll CU. Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches. Expert Opin Pharmacother. 2023 Sep-Dec;24(13):1463-1489. doi: 10.1080/14656566.2023.2228686. Epub 2023 Jun 27. PMID: 37345508.
  17. Liu-Seifert H, Osuntokun OO, Feldman PD. Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia. Compr Psychiatry. 2012 Jan;53(1):107-15. doi: 10.1016/j.comppsych.2010.12.003. Epub 2011 Feb 9. PMID: 21310400.
  18. Lui SSY, Lam JPY, Lam JWS, Chui WWH, Mui JHC, Siu BWM, Cheng KM, Cheung EFC, Chan RCK. Cognitive insight is correlated with cognitive impairments and contributes to medication adherence in schizophrenia patients. Asian J Psychiatr. 2021 Jun;60:102644. doi: 10.1016/j.ajp.2021.102644. Epub 2021 Apr 6. PMID: 33862475.
  19. IvanovMV, KosterinDN. Long-term outcomes of long-acting injection antipsychotic treatment in patients with schizophrenia. Siberian Herald of Psychiatry and Addiction Psychiatry. 2017; 3 (96): 84-91. doi: 10.26617/1810-3111-2017-3(96)-84-91 (in Russian).
  20. Harmanci P, Budak FK. The effect of psychoeducation based on motivational interview techniques on medication adherence, hope, and psychological well-being in schizophrenia patients. Clin Nurs Res. 2022 Feb;31(2):202-216. doi: 10.1177/10547738211046438. Epub 2021 Oct 1. PMID: 34596461.
  21. Xu F, Zhang H. The application of cognitive behavioral therapy in patients with schizophrenia: A review. Medicine (Baltimore). 2023 Aug 11;102(32):e34827. doi: 10.1097/MD.0000000000034827. PMID: 37565853; PMCID: PMC10419479.